Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model
This model successfully described the PK of encorafenib over time and across tumor types. No dose modifications are suggested on the basis of intrinsic or extrinsic factors evaluated.
Authors
- Yazdi K. Pithavala (ORCID: https://orcid.org/0000-0003-2301-0538)
- Joseph Piscitelli (ORCID: https://orcid.org/0009-0009-1174-966X)
- Jennifer Hibma (ORCID: https://orcid.org/0000-0002-6547-2186)
- Derek Z. Yang
- Erik M. Hahn
Institutions
- Pfizer (United States) (US)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s40262-025-01608-y
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer